Dorzagliatin in Pancreatic Insufficient Cystic Fibrosis

NCT06995651 | Recruiting Phase 1 DMC FDA Drug

• 1 other identifier: 858421
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 2

Brief Summary

This study is designed to determine the pharmacokinetic and pharmacodynamic response of dorzagliatin 50 mg twice daily following 7-day administration in individuals with pancreatic insufficient cystic fibrosis and abnormal glucose tolerance when compared to randomized, double-blind 7-day administration of placebo in a cross-over fashion. We hypothesize that dorzagliatin administration will result in significant drug concentrations and improved glucose tolerance, early-phase insulin secretion, glucagon suppression, and hepatic glycogen storage assessed during a standardized mixed-meal tolerance test.

Conditions

Pancreatic Insufficiency; Cystic Fibrosis-related Diabetes

Outcome Measures

Primary Outcomes (2)

• Drug concentrations (PK; Cmax)

  Assessed by the peak glucose during a standardized mixed-meal tolerance test following 7-day administration of study drug

  2 months

• Glucose tolerance (PD)

  2 months

Secondary Outcomes (2)

• Early-phase insulin secretion

  2 months

• Glucagon suppression

  2 months

Study Arms (2)

Dorzagliatin

EXPERIMENTAL

Dorzagliatin 50 mg orally twice daily for 7 days

Drug: Dorzagliatin; Drug: Placebo

Placebo

PLACEBO COMPARATOR

matched-placebo orally twice daily for 7 days

Drug: Dorzagliatin; Drug: Placebo

Interventions

Dorzagliatin DRUG

Randomized, double-blind, cross-over study of Dorzagliatin 50 mg orally twice daily for 7 days compared to matched-placebo orally twice daily for 7 days.

Dorzagliatin; Placebo

Placebo DRUG

Randomized, double-blind, cross-over study of Dorzagliatin 50 mg orally twice daily for 7 days compared to matched-placebo orally twice daily for 7 days.

Dorzagliatin; Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Provision of signed and dated informed consent form.
• Stated willingness to comply with all study procedures and availability for the duration of the study.
• Male or female, aged ≥18 years on date of consent.
• Confirmed diagnosis of CF, defined by positive sweat test or CFTR mutation analysis according to CFF diagnostic criteria.
• Pancreatic insufficiency defined by clinical requirement for pancreatic enzyme replacement.
• Abnormal glucose tolerance defined by OGTT criteria for EGI, IGT, or CFRD, or diagnosed CFRD.
• There will be no restriction on enrollment of individuals with CFRD but without fasting hyperglycemia (fasting hyperglycemia is defined as fasting glucose ≥126 mg/dL)
• a. Individuals with CFRD and fasting hyperglycemia (defined as above or by the use of basal insulin therapy) must also have a HbA1c ≤8% and a random (non-fasting) C- peptide ≥1.2 ng/mL \[15\].
• For females of reproductive potential: use of highly effective contraception method for the during of study participation; oral contraceptives, intra-uterine devices, Norplant®, Depo- Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable.

You may not qualify if:

• Established diagnosis of non-CF diabetes (e.g. type 1 diabetes).
• Pregnancy or lactation; a negative urine pregnancy test will be required at enrollment.
• Pulmonary exacerbation requiring IV antibiotics or systemic glucocorticoids within 4 weeks prior to randomization.
• Treatment with either CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, indinavir, ritonavir, saquinavir, telithromycin, boceprevir, nelfinavir, telaprevir, conivaptan, nefazodone, etc.) or inducers (e.g. phenobarbital, other barbiturates, carbamazepine, phenytoin, rifampicin, dexamethasone, etc.).
• Use of herbal remedies, including St. John's Wort within 14 days prior to dosing.
• Change in CFTR modulator therapy in the previous 3 months.
• History of clinically symptomatic pancreatitis within the last year.
• Prior lung, liver or another solid organ transplant.
• Abnormal kidney function: creatinine \>2x upper limit of normal (ULN) or potassium \>5.5mEq/L on non-hemolyzed specimen.
• Abnormal liver function: persistent elevation of liver function tests \>2.0 times ULN.
• Uncontrolled hyperlipidemia: triglycerides \>500 or cholesterol \>250 mg/dl.
• Hyperuricemia: serum uric acid \>1.5 times ULN.
• Anemia: hemoglobin \<10 g/dL.
• History of any illness or condition that, in the opinion of the investigator might confound the results of the study or pose an additional risk to the subject.

Sponsors & Collaborators

• University of Pennsylvania: lead

Study Sites (2)

Hospital of University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

RECRUITING

University of Pennsylvania Center for Human Phenomic Science (CHPS)

Philadelphia, Pennsylvania, 19104, United States

RECRUITING

MeSH Terms

Conditions

Exocrine Pancreatic Insufficiency

Interventions

Dorzagliatin

Condition Hierarchy (Ancestors)

Pancreatic Diseases; Digestive System Diseases

Study Officials

• Michael R Rickels, MD, MS

  University of Pennsylvania

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Paola Alvarado, MSCR

CONTACT

215-746-2081; Paola.Alvarado@Pennmedicine.upenn.edu

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 8, 2025
• First Posted: May 29, 2025
• Study Start: October 21, 2025
• Primary Completion (Estimated): July 1, 2027
• Study Completion (Estimated): July 1, 2027
• Last Updated: April 9, 2026

Record last verified: 2026-04

Locations

US (2)